Knowledge Check

Exam-style MCQs aligned with these notes. Available to Hyperexcision Scholar members.

Log in to access
Last updated: June 24, 2026Bookmark

Primary ovarian neoplasms are tumours that arise from the ovaries, fallopian tubes, or peritoneum. Malignant ovarian tumours are one of the deadliest cancers because they present with vague symptoms and are often diagnosed late.

Classification of ovarian tumours

CategoryDescriptionExamples
Ovarian epithelial tumours (65 – 70%)These are derived from the ovarian surface epithelium. They are slow growing and usually advanced at diagnosis (Stage IIIC is the most common stage). They are associated with BRCA mutations.Serous cystadenoma, serous cystadenocarcinoma, mucinous cystadenoma, mucinous cystadenocarcinoma, endometriod carcinoma, clear cell carcinoma, and Brenner tumour
Ovarian germ cell tumors (< 15 – 20%)These are derived from germ (egg) cells. They are common in women < 20 years old and are rapidly growing. They are commonly diagnosed at stage 1Immature teratoma, mature teratoma, monodermal teratoma, dysgerminoma, endodermal sinus tumour, choriocarcinoma, embryonal carcinoma, and polyembryoma
Sex cord-stromal tumours (5 – 10%)These are derived from hormone producing cells in the interstitium of the ovary. They produce hormones which cause symptoms that may not be seen with other tumours.Granulosa-theca tumour, sertoli-leydig tumour, and fibroma

Benign vs malignant ovarian masses

Benign ovarian massMalignant ovarian mass
Size< 8cm> 8cm
ConsistencyCysticSolid or mixed
Solid componentNoneNodular or papillary
SepatationsNone or singleMultilocular and thick
DopplerNegativePositive
LateralityUnilateralBilateral
Associated featuresCalcificationAscites, peritoneal metastases, and lymphadenopathy

Ovarian tumor markers

TumorTumor marker
EpithelialCA-125
DysgerminomaLDH
Endodermal sinus tumorAFP
ChoriocarcinomahCG
Embryonal carcinomaAFP + hCG

Staging ovarian cancer by surgical laparotomy

Diagnosis5-year survival
Stage IConfined to ovaries28%92%
IA1 ovary
IB2 ovaries
IC1 or 2 ovaries + Capsule rupture/Tumor at suface/Malignant ascites
Stage II1 or 2 ovaries + pelvic extension8%70%
IIAUterus/Tubes
IIBOther pelvic organs
IICA/B with Malignant ascites
Stage III1 or 2 ovaries + Peritoneal Mets/Regional lymph nodes50%39%
IIIAMicro peritoneal mets
IIIBMacro < 2cm peritoneal mets
IIICMacro > 2cm peritoneal mets/ regional LNs mets
Stage IVDistant mets beyond peritoneal cavity13%17%
  • Risk factors
  • Protective factors
  • Associated conditions
    • BRCA1/BRCA2 mutations
    • Li-Fraumeni syndrome (TP53)
    • Peutz-Jeghers syndrome (STK11)
    • Lynch syndrome
  • Signs and symptoms
    • Asymptomatic until advanced
    • Vague lower abdominal pain
    • Abdominal distension
    • Bloating
    • Early satiety
    • Pelvic pressure
    • Increased frequency and urgency
    • “Sister Mary Joseph Nodule” represents metastasis to umbilicus
    • Meigs Syndrome
      • Ovarian tumor
      • Ascites
      • Right hydrothorax
  • Physical exam finding
  • Investigation
    • Ultrasoun dis the first line investigation
      • Multiple septations
      • Cystic and solid components
      • Larger than cysts > 7cm
      • Neovascularization
    • CA-125 titres for post-menopausal women
    • Abdominopelvic CT to planning treatment
    • Laparotomy for staging and treatment
  • Treatment
    • ≤ Stage IB
      • Laparotomy
      • Peritoneal washings or aspiration of free ascitic fluid
      • Palpation of peritoneal surfaces
      • Extrafascial hysterectomy and BSO
      • Unilateral SO can be done for young women with cancer confined to one ovary
      • Peritoneal biopsy
      • Pelvic and infrarenal para-aortic lymphadenectomy
    • ≥ Stage IC
      • Chemotherapy (platinum based)
    • Dialysis or nephrostomy tubes for hydronephrosis
    • Follow-up with regular pelvic exams and CA-125 titres
Reference Intervals ›
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator ›

Leave a Reply